Howard Visit 2: A 45-year-old male with hypercholesterolemia, psoriasis, and a family history of cardiac disease

Curriculum:
Jae, a 55-year-old Korean-American male with treated hypertension presenting for routine physical
Credits:
0.5 ACPE 0.5 ANCC Contract Hours 0.5 CDR 0.5 AMA PRA Category 1 Credit(s)™
Launch Date:
25-Feb-10
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

Tara Lynn Dall, MD

Tara Lynn Dall, MD
Medical Director/President
Advanced Lipidology
Delafield, WI

Tara Dall, MD, graduated in the first class of Diplomates of the American Board of Clinical Lipidology. She was Board-Certified in Clinical Lipidology November 2005, and is one of a handful of United States physicians treating pediatric dyslipidemia. Her clinic has recently become the first fully certified lipid clinic in the United States. She attended University of Wisconsin Madison for undergraduate, medical school training and family medicine residency. Entering private practice in 2001, she formed the Cholesterol & Lifestyle Center in 2006 with the goal of aggressive detection and treatment of atherosclerotic cardiovascular disease. In 2008 she formed Advanced Lipidology, SC Early Detection Center for Heart Disease and Diabetes. She has a special interest in advanced lipid testing and CIMT technology, women's heart disease, polycystic ovarian syndrome and pediatric obesity. She is involved in CIMT research in collaboration with University of Wisconsin Madison and serves as clinical preceptor for Medical College of Wisconsin medicine residents.
 
Because of her passion and expertise, Dr. Dall has been asked to lecture in every venue from hospital and medical school grand rounds to large scale community events. She also has appeared on CNN Radio, Milwaukee's FOX News, WISN-TV, Reach MD Satellite Radio, RadioHealth Journal and has been a keynote speaker for the American Heart Association GO RED for women community events.
 
Dr. Dall is an elected board member of the Midwest Lipid Association. Other hobbies include competitive ballroom dancing and photography.

Peter H. Jones, MD

Peter H. Jones, MD
Associate Professor of Medicine
Section of Atherosclerosis and Lipid Research
Methodist Debakey Heart and Vascular Center
Baylor College of Medicine
Center for Cardiovascular Disease Prevention
Director, Weight Management Center
The Methodist Hospital
Houston, TX

Peter H. Jones, MD, is an Associate Professor of Medicine and a Co-Director of the Lipid Metabolism and Atherosclerosis Clinic in the Section of Atherosclerosis and Vascular Medicine at Baylor College of Medicine in Houston, Texas. Dr. Jones is also a member of the Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart and Vascular Center in Houston. He is a specialist in the clinical management of lipid disorders and has participated in numerous clinical trials of various drugs and their effects on lipid metabolism, including all of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Dr. Jones served as Chair of the Morbidity/Mortality Review Committee for the Lipoprotein Coronary Atherosclerosis Study (LCAS); for this study, the angiographic evaluation of fluvastatin effectiveness was performed at Baylor College of Medicine. He also served as Director of the American Heart Association Lipid Disorders Training Program at Baylor College of Medicine, which involved lectures and workshops on the clinical management of dyslipidemias. Most recently, he participated in obesity drug studies, particularly involving leptin. Dr. Jones is the Medical Director of the Methodist Wellness Services at The Methodist Hospital. He sees private patients for treatment of lipid disorders and for general medical care and serves as an attending physician in general medicine at The Methodist Hospital, the Ben Taub General Hospital, and the Michael E. DeBakey Veterans Affairs Medical Center.
1. Apply evidence-based strategies for the prevention, screening, and treatment of atherosclerosis risk factors and their comorbidities to clinical practice
2. Evaluate current and novel markers for atherosclerosis and their potential applications for CV risk detection and management, as well as their limitations
3. Optimize treatment strategies utilizing dose titration and combination therapy that may support better clinical outcomes
4. Implement effective behavioral modification and counseling strategies to encourage patient compliance to therapies
5. Incorporate appropriate treatment strategies for special risk populations, including minorities and women